IDEXX Laboratories (NASDAQ:IDXX) increased its financial projections for 2026 following a first quarter marked by robust demand for pet healthcare services and significant margin expansion within its core diagnostic segments.
BrightSpring Health Services (NASDAQ:BTSG) reported a landmark first quarter for 2026, delivering substantial growth across all key financial metrics.
Kodiak Sciences (NASDAQ:KOD) is set to present a series of clinical and preclinical advances at the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings between May 2 and May 7, 2026.
Pentair (NYSE:PNR) reported a strong start to the 2026 fiscal year, characterized by steady sales growth and a significant expansion in operating efficiency.
Johnson & Johnson (NYSE:JNJ) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipocalimab-aahu).
UnitedHealth Group (NYSE:UNH) today reported financial results for the first quarter of 2026, delivering growth across its primary business platforms and raising its full-year earnings outlook.
Hims & Hers Health (NYSE:HIMS) shares surged this week, closing 13.7% higher after the U.S. Food and Drug Administration (FDA) announced a high-stakes meeting to re-evaluate the regulatory status of several popular peptides.
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company specializing in chronic infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV).
Labcorp (NYSE:LH), a global leader in innovative laboratory services, has announced the launch of the Labcorp Fentanyl Urine Visual Test.
Herbalife (NYSE:HLF) announced preliminary financial results for the first quarter of 2026 on Tuesday, reporting that net sales growth and adjusted earnings are expected to surpass the high end of its previously issued guidance.
Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.
Priovant Therapeutics, a majority-owned subsidiary of Roivant Sciences (NASDAQ:ROIV), provided a significant update on its late-stage immunology pipeline on Thursday, April 2, 2026.
